Financial results for quarterly & year ended 31st March 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Kabra Drugs Ltd reported standalone revenue from operations of Rs. 9,274 Lakhs for FY2026, with net profit after tax of Rs. 495.98 Lakhs compared to a net loss of Rs. 108.56 Lakhs in the prior year. EPS improved to Rs. 2.09 from a negative Rs. 0.99. The company restated prior quarter figures due to first-time application of Ind AS 116 (Leases), reversing Rs. 4.32 Lakhs in rent expense and recognising Rs. 3.41 Lakhs in depreciation and Rs. 1.66 Lakhs in finance costs. Operating cash flow was deeply negative at Rs. 947.43 Lakhs, primarily due to a sharp rise in trade receivables to Rs. 7,077.60 Lakhs (up from Rs. 60.05 Lakhs), raising working capital concerns. The auditor issued an unmodified opinion. The company also switched to the concessional tax regime under Section 115BAA, increasing current tax expense to Rs. 75.54 Lakhs.
Strong turnaround from loss to profit, but the sharp surge in trade receivables and negative operating cash flow are concerning and warrant scrutiny on collection quality. Shareholders should monitor whether receivables are eventually realised.